AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32318872 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary video consultations
Number of subjects: 100
Study 34151818 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Therapy (PMRT)
Number of subjects: 37
Study 34151818 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapies (non-PMRT group)
Number of subjects: 37
Study 32106141 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (600 mg daily with NRTIs)
Number of subjects: 72
Study 32106141 — intervention group
Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (300/100 mg daily with NRTIs)
Number of subjects: 72
Study 32106141 — intervention group
Group type: COMPARATOR
Intervention: Control (no antiretrovirals)
Number of subjects: 72
Study 33657959 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg nano-curcumin
Number of subjects: 40
Study 33657959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32328824 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐POEM (Gastric peroral endoscopic myotomy)
Number of subjects: 216
Study 32328824 — intervention group
Group type: COMPARATOR
Intervention: Endoscopist experience with <20 G‐POEM procedures
Number of subjects: 216
Study 32328824 — intervention group
Group type: COMPARATOR
Intervention: Endoscopist experience with >20 G‐POEM procedures
Number of subjects: 216
Study 35854236 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) every 3 weeks during concurrent chemoradiotherapy and once every 6 weeks after consolidation chemotherapy for up to 1 year.
Number of subjects: 0
Study 35854236 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with intensity modulated radiotherapy and high‐dose rate brachytherapy, along with weekly DDP (40 mg/m2) during radiotherapy and 6 cycles of consolidated chemotherapy (paclitaxel plus DDP) after radiotherapy.
Number of subjects: 0
Study 33130851 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (ApoB)
Number of subjects: 24925
Study 35666852 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS) low dose: 0.35 or 0.5 mg; high dose: 1.4 or 2.0 mg
Number of subjects: 37
Study 35666852 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide oral suspension (BOS)
Number of subjects: 37
Study 35666852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 34027030 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (20 mg daily for two weeks followed by 40 mg daily for two weeks)
Number of subjects: 46
Study 34027030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 34027030 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (in subgroup with systolic blood pressure < 110 mmHg)
Number of subjects: 46
Study 34027030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup with systolic blood pressure < 110 mmHg)
Number of subjects: 46
Study 32133907 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT
Number of subjects: 38
Study 32133907 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 38
Study 35045980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (100 mL oral dose)
Number of subjects: 20
Study 33064487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrene dimerization at various temperatures (600, 900, 1200, 1600, and 2000 K) with collisional impact parameters (0‐18 Å)
Number of subjects: 1000
Study 34370975 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of renin-angiotensin system inhibitors
Number of subjects: 0
Study 34370975 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of renin-angiotensin system inhibitors
Number of subjects: 0
Study 32402681 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with bevacizumab (6 cycles of FOLFOX/FOLFIRI before and after surgery)
Number of subjects: 76
Study 32402681 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy with bevacizumab (12 cycles after surgery)
Number of subjects: 76
Study 32402681 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with bevacizumab (in subgroup with CEA ≥ 5 ng/mL)
Number of subjects: 76
Study 32402681 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with bevacizumab (in subgroup with over 2 liver metastases)
Number of subjects: 76
Study 32468087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangibotide (0.3, 1.0, or 3.0 mg/kg/h)
Number of subjects: 49
Study 32468087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nangibotide
Number of subjects: 49
Study 32468087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 36104719 — intervention group
Group type: EXPERIMENTAL
Intervention: MRV-MNP and placebo (0.9% sodium chloride) subcutaneous injection
Number of subjects: 285
Study 36104719 — intervention group
Group type: COMPARATOR
Intervention: Placebo MNP and MRV by subcutaneous injection (MRV-SC)
Number of subjects: 285
Study 36104719 — intervention group
Group type: EXPERIMENTAL
Intervention: MRV-MNP
Number of subjects: 285
Study 36104719 — intervention group
Group type: COMPARATOR
Intervention: MRV-SC
Number of subjects: 285
Study 33705543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle or metformin interventions
Number of subjects: 1876
Study 33705543 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1876
Study 33705543 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 1876
Study 33705543 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants without diabetes
Number of subjects: 1876
Study 32028783 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 42
Study 32028783 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 42
Study 35767567 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse homology approach using contrastive learning for IDRs
Number of subjects: 0
Study 35767567 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse homology approach
Number of subjects: 0
Study 32060605 — intervention group
Group type: EXPERIMENTAL
Intervention: LOPOSAM technique
Number of subjects: 22
Study 32060605 — intervention group
Group type: COMPARATOR
Intervention: Rubin JP technique
Number of subjects: 22
Study 32060605 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 22
Study 34118609 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral pyridoxine (100-300 mg/kg/day) in combination with ACTH (150 IU/m2/day)
Number of subjects: 80
Study 34118609 — intervention group
Group type: COMPARATOR
Intervention: Standard ACTH therapy alone
Number of subjects: 80
Study 35235659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 48
Study 35235659 — intervention group
Group type: COMPARATOR
Intervention: Exenatide (EXE), 5 μg s.c.
Number of subjects: 48
Study 35235659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (DAPA), 10 mg
Number of subjects: 48
Study 35235659 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPA/EXE
Number of subjects: 48
Study 35835685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (36 min, three times weekly for one month)
Number of subjects: 23
Study 35835685 — intervention group
Group type: COMPARATOR
Intervention: Observation (one month)
Number of subjects: 23
Study 35835685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (after observation)
Number of subjects: 23
Study 35835685 — intervention group
Group type: COMPARATOR
Intervention: Observation (before acupressure)
Number of subjects: 23
Study 32800438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bikini incision
Number of subjects: 0
Study 32800438 — intervention group
Group type: COMPARATOR
Intervention: Traditional longitudinal incision (control)
Number of subjects: 0
Study 33957098 — intervention group
Group type: EXPERIMENTAL
Intervention: High construal/promotion focus advertisement
Number of subjects: 191
Study 33957098 — intervention group
Group type: COMPARATOR
Intervention: Low construal/prevention focus advertisement
Number of subjects: 191
Study 33027644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRA)
Number of subjects: 0
Study 33620714 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation + behavioral incentives (PNBI)
Number of subjects: 150
Study 33620714 — intervention group
Group type: COMPARATOR
Intervention: Assessment + standard care (ASC)
Number of subjects: 150
Study 34693933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) based ART
Number of subjects: 52
Study 34693933 — intervention group
Group type: COMPARATOR
Intervention: Nonnucleoside reverse transcriptase inhibitor (nNRTI) based ART
Number of subjects: 52
Study 34693933 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-to-clearance
Number of subjects: 52
Study 33966435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 1
Study 33567423 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (800 mg + 5 μg Vitamin D)
Number of subjects: 55
Study 33567423 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (1,000 mg)
Number of subjects: 55
Study 32343193 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted electronic outreach
Number of subjects: 114
Study 32343193 — intervention group
Group type: COMPARATOR
Intervention: Banner ads on social media
Number of subjects: 114
Study 32330183 — intervention group
Group type: EXPERIMENTAL
Intervention: Food pictures
Number of subjects: 0
Study 32330183 — intervention group
Group type: COMPARATOR
Intervention: Non-food pictures
Number of subjects: 0
Study 32330183 — intervention group
Group type: EXPERIMENTAL
Intervention: Food pictures followed by milkshake
Number of subjects: 0
Study 32744441 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing basal heart rate (BHR) categorized into <60 bpm, 60-89 bpm, and ≥90 bpm.
Number of subjects: 1349
Study 32744441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean diastolic blood pressure
Number of subjects: 1349
Study 32744441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose
Number of subjects: 1349
Study 32847991 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposures (22 agents)
Number of subjects: 882
Study 32847991 — intervention group
Group type: COMPARATOR
Intervention: Control group (521 women without lung cancer)
Number of subjects: 882
Study 33280953 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity resistance training (RTG)
Number of subjects: 48
Study 33280953 — intervention group
Group type: COMPARATOR
Intervention: Sham resistance training (CG)
Number of subjects: 48
Study 33798731 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH intervention (online portal and twice a month phone calls from a PA coach)
Number of subjects: 30
Study 33798731 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (self-help PA handout and twice a month general health newsletter)
Number of subjects: 30
Study 33798731 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH intervention
Number of subjects: 30
Study 35954922 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention (4-week duration, individualized and customized exercise program)
Number of subjects: 32
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ITT analysis
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ITT analysis
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants completing the trial for primary outcome
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants included in analysis for primary outcome
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing primary outcome data >20%
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Missing primary outcome data 10%-20%
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of missing data handling
Number of subjects: 160
Study 34330848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis utilization
Number of subjects: 160
Study 32690508 — intervention group
Group type: EXPERIMENTAL
Intervention: SPOON behavioural change strategy and SQ-LNS
Number of subjects: 1628
Study 32690508 — intervention group
Group type: EXPERIMENTAL
Intervention: SPOON behavioural change strategy and micronutrient powders
Number of subjects: 1628
Study 32690508 — intervention group
Group type: COMPARATOR
Intervention: Standard of care provided by the Ministry of Health (micronutrient powders)
Number of subjects: 1628
Study 35073865 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAPS intervention (nurse-led care management program)
Number of subjects: 140
Study 32071367 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized plus optimized nutrition (experimental)
Number of subjects: 120
Study 32071367 — intervention group
Group type: COMPARATOR
Intervention: Optimized nutrition alone (controls)
Number of subjects: 120
Study 35289043 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.005% solution
Number of subjects: 30
Study 35289043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32145111 — intervention group
Group type: EXPERIMENTAL
Intervention: ixazomib-lenalidomide-dexamethasone (IRd)
Number of subjects: 0
Study 32145111 — intervention group
Group type: COMPARATOR
Intervention: placebo-lenalidomide-dexamethasone (placebo-Rd)
Number of subjects: 0
Study 32568601 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend physical therapy services in the sub-acute setting (Phase 2, n = 130)
Number of subjects: 247
Study 32568601 — intervention group
Group type: COMPARATOR
Intervention: Weekend physical therapy services in the acute setting (Phase 1, n = 117)
Number of subjects: 247
Study 33913511 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg via subcutaneous injection at baseline, week 1-4, and then every 4 weeks until week 48
Number of subjects: 853
Study 33913511 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50
Number of subjects: 853
Study 33913511 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 853
Study 33913511 — intervention group
Group type: COMPARATOR
Intervention: adalimumab 40 mg
Number of subjects: 853
Study 34216334 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent incarceration (within the past three months)
Number of subjects: 1482
Study 34216334 — intervention group
Group type: COMPARATOR
Intervention: Never incarcerated or previously incarcerated but not in the past three months
Number of subjects: 1482
Study 33913217 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing and health education
Number of subjects: 84
Study 33913217 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 84
Study 32730096 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment
Number of subjects: 44
Study 32730096 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted Pivotal Response Treatment
Number of subjects: 44
Study 32730096 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 44
Study 35596774 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg once daily for 6 months
Number of subjects: 64
Study 35596774 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 64
Study 35596774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 34585747 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual AUD symptoms (1 vs. no symptoms) at 6 months
Number of subjects: 323
Study 34585747 — intervention group
Group type: EXPERIMENTAL
Intervention: AUD remission
Number of subjects: 323
Study 34585747 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed reduction/cessation of alcohol use
Number of subjects: 323
Study 34371209 — intervention group
Group type: COMPARATOR
Intervention: anodal tDCS
Number of subjects: 150
Study 34371209 — intervention group
Group type: COMPARATOR
Intervention: high-frequency tRNS + DC-offset
Number of subjects: 150
Study 34371209 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 150
Study 33008395 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased Blautia
Number of subjects: 0
Study 33008395 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated γ‐aminobutyric acid (GABA)
Number of subjects: 0
Study 33008395 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased Enterobacteriaceae family
Number of subjects: 0
Study 33008395 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased Gammaproteobacteria class
Number of subjects: 0
Study 33008395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut production of serotonin
Number of subjects: 0
Study 33008395 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically increased Bacilli class
Number of subjects: 0
Study 34920155 — intervention group
Group type: COMPARATOR
Intervention: 0.05% sodium fluoride (F, positive control)
Number of subjects: 22
Study 34920155 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mM calcium lactate solution followed by 0.05% sodium fluoride solution (Ca→F)
Number of subjects: 22
Study 34920155 — intervention group
Group type: COMPARATOR
Intervention: 150 mM calcium lactate solution premixed with 0.05% sodium fluoride solution (CaF2, active control)
Number of subjects: 22
Study 34920155 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (negative control)
Number of subjects: 22
Study 32744373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated hospital-initiated transitional care programme for 6 months
Number of subjects: 270
Study 32744373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated hospital-initiated transitional care programme
Number of subjects: 270
Study 32744373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transitional care programme)
Number of subjects: 270
Study 33827659 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive pre‐pregnancy lifestyle intervention to promote weight loss with ongoing treatment until conception
Number of subjects: 252
Study 33827659 — intervention group
Group type: COMPARATOR
Intervention: Educational control group
Number of subjects: 252
Study 33827659 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive pre‐pregnancy lifestyle intervention
Number of subjects: 252
Study 32553151 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-DGAT2Rx (250 mg, once weekly for 13 weeks)
Number of subjects: 44
Study 32553151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 32553151 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS-DGAT2Rx
Number of subjects: 44
Study 33836158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine plus alcohol
Number of subjects: 0
Study 33836158 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine plus alcohol
Number of subjects: 0
Study 34060185 — intervention group
Group type: EXPERIMENTAL
Intervention: computerised speechreading training for three weeks
Number of subjects: 92
Study 34060185 — intervention group
Group type: COMPARATOR
Intervention: business‐as‐usual controls
Number of subjects: 92
Study 33211592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 33211592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (4.03 mmol) of inorganic nitrate
Number of subjects: 14
Study 33211592 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (8.06 mmol) of inorganic nitrate
Number of subjects: 14
Study 35440710 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Start
Number of subjects: 4442
Study 33443699 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring after discharge
Number of subjects: 409
Study 33443699 — intervention group
Group type: COMPARATOR
Intervention: Not referred for remote monitoring
Number of subjects: 409
Study 32936675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A: Requiring ICU clinicians to document a functional prognostic estimate
Number of subjects: 0
Study 32936675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B: Providing justification if not offering comfort-focused care
Number of subjects: 0
Study 32936675 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions A + B
Number of subjects: 0
Study 32936675 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 35329415 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Exercises (BE)
Number of subjects: 61
Study 35329415 — intervention group
Group type: COMPARATOR
Intervention: Yoga (Y)
Number of subjects: 61
Study 35329415 — intervention group
Group type: COMPARATOR
Intervention: Pilates (P)
Number of subjects: 61
Study 35329415 — intervention group
Group type: COMPARATOR
Intervention: Interval-Training (IT)
Number of subjects: 61
Study 34819434 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (open reduction and internal fixation using tension band wiring)
Number of subjects: 34
Study 34819434 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment (boot cast)
Number of subjects: 34
Study 34819434 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 34
Study 34819434 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 34
Study 32845968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1089
Study 36055813 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/adavosertib (arm A)
Number of subjects: 55
Study 36055813 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/placebo (arm B)
Number of subjects: 55
Study 33817992 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% N2O
Number of subjects: 65
Study 33817992 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N2O
Number of subjects: 65
Study 33817992 — intervention group
Group type: COMPARATOR
Intervention: 0% N2O
Number of subjects: 65